6.36
-0.4(-5.92%)
Currency In USD
| Previous Close | 6.76 |
| Open | 6.91 |
| Day High | 6.93 |
| Day Low | 6.3 |
| 52-Week High | 11.41 |
| 52-Week Low | 1.73 |
| Volume | 566,869 |
| Average Volume | 821,579 |
| Market Cap | 197.17M |
| PE | -3.42 |
| EPS | -1.86 |
| Moving Average 50 Days | 8.4 |
| Moving Average 200 Days | 5.42 |
| Change | -0.4 |
If you invested $1000 in Sagimet Biosciences Inc. (SGMT) since IPO date, it would be worth $398.75 as of September 16, 2025 at a share price of $6.36. Whereas If you bought $1000 worth of Sagimet Biosciences Inc. (SGMT) shares 1 year ago, it would be worth $1,817.14 as of September 16, 2025 at a share price of $6.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
GlobeNewswire Inc.
Sep 10, 2025 11:00 AM GMT
SAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announce
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 26, 2025 11:00 AM GMT
SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that man
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 05, 2025 11:00 AM GMT
SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that man